Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions in patients with fibrodysplasia ossificans progressiva (FOP) Regeneron plans to discuss regulatory submission with regulatory...
Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks Interim data support candidates’ potential to become foundational NASH therapies Top-line data from full...
– First subject treated in SYNB1891 immuno-oncology study, data from monotherapy arm expected in 2020 – – Expansion of pipeline with new preclinical programs in secondary hyperoxaluria and maple syrup urine disease (MSUD) – – Phase 2 clinical trial of solid...
NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first pancreatic cancer patient has been dosed in Part 2 of the...
Sites now have access to a free eRegulatory application to simplify regulatory compliance and speed study execution PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE:VEEV) today announced the availability of Veeva SiteVault Free, a free eRegulatory...
Email
Text